What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Robert L. Coleman mainly focuses on Ovarian cancer, Internal medicine, Oncology, Cancer and Cancer research.
His studies deal with areas such as Chemotherapy, Docetaxel, Targeted therapy, Disease and Biomarker as well as Ovarian cancer.
Robert L. Coleman combines subjects such as Gastroenterology, Gynecology and Surgery with his study of Internal medicine.
His Oncology research is multidisciplinary, relying on both Veliparib, Clinical trial, Fallopian tube and Carcinoma.
Robert L. Coleman interconnects Clinical endpoint and Drug development in the investigation of issues within Cancer.
Robert L. Coleman has included themes like Germline mutation, Endocrinology, PARP inhibitor, Ovarian carcinoma and Combination therapy in his Cancer research study.
His most cited work include:
- Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma (796 citations)
- RNA interference in the clinic: challenges and future directions (580 citations)
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (554 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Oncology, Ovarian cancer, Cancer and Cancer research.
His work in Internal medicine is not limited to one particular discipline; it also encompasses Rucaparib.
His study on Gynecologic oncology is often connected to In patient as part of broader study in Oncology.
The concepts of his Ovarian cancer study are interwoven with issues in Angiogenesis, Disease, In vivo and Olaparib.
His work deals with themes such as Cell growth, Cancer cell, Docetaxel, PI3K/AKT/mTOR pathway and Pharmacology, which intersect with Cancer research.
His Chemotherapy study combines topics in areas such as Gastroenterology and Serous fluid.
He most often published in these fields:
- Internal medicine (57.91%)
- Oncology (47.47%)
- Ovarian cancer (40.91%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (57.91%)
- Oncology (47.47%)
- Ovarian cancer (40.91%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Oncology, Ovarian cancer, Chemotherapy and Cancer.
Robert L. Coleman has researched Internal medicine in several fields, including Gastroenterology, Placebo and Rucaparib.
His research in Oncology intersects with topics in Recurrent Ovarian Cancer, Maintenance therapy, PARP inhibitor and Olaparib.
His Ovarian cancer research includes themes of Stage, Targeted therapy, Clinical trial and Immunotherapy.
The various areas that Robert L. Coleman examines in his Chemotherapy study include Multivariate analysis, BRCA mutation, Serous fluid and Cohort.
His work carried out in the field of Cancer brings together such families of science as Cancer research and Intensive care medicine.
Between 2019 and 2021, his most popular works were:
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. (64 citations)
- The forefront of ovarian cancer therapy: update on PARP inhibitors. (26 citations)
- Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial. (26 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His scientific interests lie mostly in Internal medicine, Ovarian cancer, Oncology, Endometrial cancer and Clinical endpoint.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Placebo.
His Ovarian cancer research is classified as research in Cancer.
His study in the fields of Primary peritoneal carcinoma under the domain of Cancer overlaps with other disciplines such as Median body.
His Oncology study combines topics from a wide range of disciplines, such as Metastatic cervical cancer, Previously treated, Olaparib, PARP inhibitor and Maintenance therapy.
His research integrates issues of Hysterectomy, Urology, Endometrial hyperplasia, EZH2 and Gene silencing in his study of Endometrial cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
